Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

COVID-19 is a highly transmissible disease caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), affects 226 countries and continents, and has resulted in> 6.2 …

microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size,
specific targetability, and critical role in disease pathogenesis. However,< 20 miR targeting …

In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

Lung cancer is one of the most aggressive and deadliest health threats. There has been an
increasing interest in non-coding RNA (ncRNA) recently, especially in the areas of …

Bronchiectasis is a common progressive respiratory disease with recognisable radiological
abnormalities and a clinical syndrome of cough, sputum production and recurrent respiratory …

Cystic fibrosis (CF) is the most common monogenic disorder, caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene. Over the last 30 years, tremendous …

The era of innovative RNA therapies using antisense oligonucleotides (ASOs), siRNAs, and
mRNAs is beginning. Since the emergence of the concept of ASOs in 1978, it took more than …

Cystic fibrosis (CF) is the most common genetic disorder among Caucasians, estimated to
affect more than 70,000 people in the world. Severe and persistent bronchial inflammation …

Developing new effective treatment strategies to overcome the rise in multi-drug resistant
tuberculosis cases (MDR-TB) represents a global challenge. A host-directed therapy (HDT) …